This abstract evaluates a multi-cancer early detection (MCED) blood test specifically designed for individuals with obesity, a group at higher risk for several cancers often without standard screening. The study investigated the test’s ability to accurately detect cancer and identify the tissue of origin using a two-step…
What You Should Know: – Mochi Health, a physician-guided obesity care program, announced the launch of its new insurance-based plans. – These expanded offerings are designed to provide more personalized treatment experiences for patients, placing a strong emphasis on comprehensive…
The sources discuss Fractyl Health’s Rejuva GLP-1 gene therapy platform, highlighting preclinical data presented at ASGCT 2025 for its candidate RJVA-001. This research indicates that a single dose of RJVA-001 in animal models durably improves metabolic markers related to type 2 diabetes and obesity, achieving…
ChatGPTMay 26, 2025 Fatigue or low energy is a commonly reported side effect among users of GLP-1 receptor agonists like semaglutide (Ozempic/Wegovy) or tirzepatide (Mounjaro/Zepbound), but it is not as well characterized or studied as gastrointestinal effects. Here’s what is…
WSJ article discusses the growing trend of microdosing GLP-1 medications, like Ozempic and Zepbound, which are primarily used for weight loss and diabetes management. Some individuals are taking smaller or less frequent doses than prescribed, often motivated by cost savings, a desire…
This scientific article examines the connection between aging and metabolic changes in humans. It focuses on age-related alterations in adipose tissue, muscle, and liver, noting how sedentary habits worsen these effects, while physical activity can help mitigate them. The text also explores potential therapeutic interventions, including caloric…
Glucagon-like peptide-1 receptor agonists compared with bariatric metabolic surgery and the risk of obesity-related cancer: an observational, retrospective cohort studyWolff Sagy, Yael et al. eClinicalMedicine, Volume 83, 103213 This paper presents an observational, retrospective cohort study comparing the incidence of obesity-related cancer (ORC) in…
There is a significant burden of chronic diseases in the United States, comparing its rates to other developed nations. One source from the Peterson-KFF Health System Tracker points out that the U.S. has higher rates of many chronic illnesses, including obesity, diabetes, and…
This systematic review and meta-analysis investigated the rate of weight regain after people stopped using GLP-1 receptor agonists (GLP-1 RAs) for weight management. The researchers identified relevant studies and analyzed the weight loss achieved during treatment and the subsequent weight increase once medication stopped. Their findings indicate that participants regain a significant amount…
Global burden and strength of evidence for 88 risk factors in204 countries and 811 subnational locations, 1990–2021 : a systematic analysis for the Global Burden of Disease Study 2021 Lancet May 18, 2024 GBD 2021 Risk Factors Collaborators. Global burden…